Valuation: Becton, Dickinson and Company

Market Cap 43.79B 38.49B 35.83B 32.91B 61.79B 4,199B 62.61B 426B 166B 2,074B 164B 161B 7,167B P/E 2026 *
39.6x
P/E 2027 * 30.6x
Enterprise Value 60.3B 53.01B 49.35B 45.32B 85.1B 5,783B 86.22B 587B 229B 2,856B 226B 221B 9,870B EV / Sales 2026 *
3.14x
EV / Sales 2027 * 2.93x
Free-Float
74.04%
Yield 2026 *
2.42%
Yield 2027 * 2.46%
Manager TitleAgeSince
Chief Executive Officer 53 27/01/2020
Director of Finance/CFO 44 04/12/2025
Compliance Officer - 31/01/2023
Director TitleAgeSince
Director/Board Member 75 23/09/2002
Director/Board Member 71 25/07/2010
Chairman 53 27/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
+1.39%-2.23% - - 43.79B
+3.48%+8.95%-14.06%-3.67% 182B
+3.72%+6.64%-4.51%-0.49% 108B
+1.90%+4.53%+10.69%+69.81% 60.54B
-4.21%-6.07%+22.50%+49.01% 50.53B
+2.43%+4.07% - - 33.57B
+2.91%+0.24%-16.31%-43.40% 28.31B
+1.41%-7.14%+29.42%-8.72% 23.31B
+4.02%+7.30%+0.30%-1.23% 21.28B
+1.78%+0.95%-11.55%+0.68% 20.27B
Average +1.89%-0.57%+2.06%+7.75% 58.63B
Weighted average by Cap. +2.31%+0.88%-2.56%+9.18%

Financials

2026 *2027 *
Net sales 19.21B 16.89B 15.72B 14.44B 27.11B 1,843B 27.47B 187B 72.99B 910B 72.12B 70.57B 3,145B 19.73B 17.34B 16.14B 14.82B 27.84B 1,892B 28.2B 192B 74.94B 934B 74.05B 72.45B 3,228B
Net income 1.12B 989M 920M 845M 1.59B 108B 1.61B 10.94B 4.27B 53.26B 4.22B 4.13B 184B 1.45B 1.27B 1.19B 1.09B 2.05B 139B 2.07B 14.1B 5.51B 68.63B 5.44B 5.32B 237B
Net Debt 16.51B 14.52B 13.51B 12.41B 23.3B 1,584B 23.61B 161B 62.74B 782B 61.99B 60.66B 2,703B 13.96B 12.27B 11.42B 10.49B 19.7B 1,339B 19.96B 136B 53.03B 661B 52.4B 51.27B 2,284B
Logo Becton, Dickinson and Company
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical management systems (52.4%): medication delivery systems, pharmaceutical systems, advanced patient monitoring systems, etc.; - interventional medical equipment (23.9%): surgical instruments, urological care products, etc.; - diagnostic materials and clinical research and development tools (23.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, tools for studying genes and culturing cells, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (58.6%), Europe/Middle East/Africa (21.6%), Asia (14.2%) and other (5.6%).
Employees
72,000
Trader
Investor
Global
Quality
ESG MSCI
-